Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 12, 2025, titled "Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India".
Press Release Mar 12 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Glenmark Pharmaceuticals Limited has announced the launch of Empagliflozin and its fixed-drug combinations in India, expanding its cardiometabolic portfolio. The new products, marketed under the brand names Glempa, Glempa-L, and Glempa-M, aim to improve glycemic control and reduce cardiovascular risks for patients with type two diabetes. This launch reflects Glenmark's commitment to providing innovative and accessible treatments in the cardiometabolic care sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Mar 10 2025
- Press Release Mar 03 2025
- Press Release Feb 27 2025
- Press Release Feb 14 2025
- Press Release Feb 12 2025
Later from Glenmark Pharmaceuticals
- Press Release Mar 20 2025
- Glenmark Pharmaceuticals Limited Press Release Apr 01 2025
- Press Release Apr 16 2025
- Press Release May 05 2025
- Press Release May 23 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals